Sandip Kapadia
2021 - Harmony Biosciences Holdings
In 2021, Sandip Kapadia earned a total compensation of $6.2M as EVP and Chief Financial Officer at Harmony Biosciences Holdings.
Compensation breakdown
| Bonus | $175,000 |
|---|---|
| Non-Equity Incentive Plan | $185,267 |
| Option Awards | $3,765,100 |
| Salary | $354,155 |
| Stock Awards | $1,741,800 |
| Other | $2,610 |
| Total | $6,223,933 |
Kapadia received $3.8M in option awards, accounting for 60% of the total pay in 2021.
Kapadia also received $175K in bonus, $185.3K in non-equity incentive plan, $354.2K in salary, $1.7M in stock awards and $2.6K in other compensation.
Rankings
In 2021, Sandip Kapadia's compensation ranked 2,032nd out of 12,406 executives tracked by ExecPay. In other words, Kapadia earned more than 83.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,032 out of 12,406 | 84th |
Division Manufacturing | 775 out of 5,492 | 86th |
Major group Chemicals And Allied Products | 302 out of 2,368 | 87th |
Industry group Drugs | 261 out of 2,089 | 88th |
Industry Pharmaceutical Preparations | 169 out of 1,536 | 89th |
Source: SEC filing on April 8, 2022.
Kapadia's colleagues
We found five more compensation records of executives who worked with Sandip Kapadia at Harmony Biosciences Holdings in 2021.
2021
Jeffrey Dierks
Harmony Biosciences Holdings
EVP and Chief Commercial Officer
2021
John Jacobs
Harmony Biosciences Holdings
Chief Executive Officer
2021
Jeffrey Dayno
Harmony Biosciences Holdings
Chief Medical Officer
2021
Andrew Serafin
Harmony Biosciences Holdings
EVP and Chief Strategy Officer
2021
Susan Drexler
Harmony Biosciences Holdings
Chief Financial Officer
News
Intercept Pharmaceuticals CEO Jerome Durso's 2021 pay jumps 101% to $7.9M
May 2, 2022
Harmony Biosciences Holdings CFO Sandip Kapadia's 2021 pay jumps 171% to $6.2M
April 8, 2022
Intercept Pharmaceuticals CEO Mark Pruzanski's 2020 pay slips 3% to $6.4M
April 27, 2021
Intercept Pharmaceuticals CEO Mark Pruzanski's 2019 pay jumps 46% to $6.6M
April 29, 2020
Intercept Pharmaceuticals CEO Mark Pruzanski's 2018 pay falls 26% to $4.5M
April 30, 2019